NFL signs Novartis

NFL signs Novartis as first pharmaceutical partner-source
The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis, a league source told Reuters on Thursday. The partnership focuses on the NFL's health initiatives,
Novartis in as first NFL pharmaceutical sponsor
American football’s elite National Football League (NFL) has brought in US medicine company Novartis as the property's first-ever pharmaceutical partner. Novartis, granted exclusivity in the corporate pharmaceutical partnership category,
NFL drafts Novartis as league’s first corporate pharma partner
Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football league and a pharmaceutical company. | Novartis has teamed up with the NFL in a multi-year partnership,
NFL signs first pharmaceutical deal with Novartis
The NFL have signed its first-ever pharmaceutical partner in a multi-year deal with Novartis to focus on the NFL’s health initiatives, including its annual health and safety summit, as well as its 'Crucial Catch' cancer awareness program.
NFL and Novartis Forge Groundbreaking Health Partnership
The NFL has inked a multi-year deal with pharmaceutical giant Novartis, marking its first such partnership. This collaboration will spotlight health initiatives like cancer awareness. It strategically aligns Novartis with the influential league amid potential U.
Novartis named first-ever corporate pharmaceutical partner of the National Football League
The long-term, exclusive pharmaceutical category agreement is designed to turn fans' passion for the game into a commitment to better health -- Novartis sports partnership covers the NFL's marquee health initiatives,
Novartis AG (NOVN) Gets a Buy from Kepler Capital
Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 13 and set a price target of ...
Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy
Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home ...
Fierce Biotech12d
Novartis hands over $55M upfront to license preclinical hives prospect from Japan's Kyorin
Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...
Reuters9d
Novartis not panicking over potential US pharmaceutical tariffs, chairman says
ZURICH, March 6 (Reuters) - Novartis (NOVN.S), opens new tab is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the drug maker's ...
Novartis Sees Unusually High Options Volume (NYSE:NVS)
Novartis AG (NYSE:NVS – Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 54,767 call options on the stock. This represents an increase of 2,389% ...
Novartis' Future Dividend Projections Appear Well Covered By Earnings
Novartis AG ( VTX:NOVN ) has announced that it will be increasing its dividend from last year's comparable payment ...
Commercial Observer4d
Pharma Company Novartis Renews 16K-SF Office at 10 Bryant Park
Swiss pharmaceutical company Novartis has renewed its 15,865-square-foot office at Property & Building Corporation’s 10 ...
Zacks Investment Research on MSN3d
Why Novartis (NVS) is a Top Value Stock for the Long-Term
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...